Reach Us +1-217-403-9671
Design, Synthesis And Bioevaluation Of Paeonol Derivatives As Potential Anti-HBV Agents | 19774
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Design, synthesis and bioevaluation of paeonol derivatives as potential anti-HBV agents

5th World Congress on Bioavailability and Bioequivalence Pharmaceutical R&D Summit

Ming-Hua Hsu

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.017

H epatitis B virus (HBV) infections are a major global health problem despite the availability of an effective vaccine. Over two billion people are infected at present and about 400 million are chronically infected carriers of this virus. Paeonol, 2-hydroxy-4-methoxy acetophenone, a major composition of the traditional Chinese medicine, peony is being used for more than thousand years. Paeonol exhibit many interesting biological activities that has been applied to anti-inflammatory, analgesic effects, antioxidant, anti-diabetic, and acaricidal activity. Herein, we report a new series of paeonol derivatives has been tested for their design, synthesis, and bioevaluation. The paeonol core was kept and a new sulfone side chain was conjugated in the phenol group. These new serious of paeonol derivatives were found to have potential anti-HBV effects in HepG2 2.2.15 cells. Among them, compound XX had the most potent inhibition activity of the IC 50 value of 16.38 μ g/mL with high selectivity index, SI (TC 50 /IC 50 ) 10.64. The newly synthesized compounds can be a structural template for designing and developing novel anti-HBV agents.
Ming-Hua Hsu has completed his PhD from Department of Chemistry, National Tsing Hua University and got Postdoctoral studies from National Cheng Kung University and Academia Sinica. He joined Nuclear Science & Technology Development Center, National Tsing Hua University from 2010, and has been working on drug design, synthesis, evaluation, and the development of Boron Neutron Capture Therapy Agents
Relevant Topics